71 results about "Immune inflammation" patented technology

The invention relates to the technical field of biomedical materials, in particular to a titanium implant multifunctional composite coating with anti-active oxygen and anti-inflammatory dual performance and a preparation method of the titanium implant multifunctional composite coating. The coating is composed of a lanthanum oxide (La2O3) nano-particle layer growing on the surface of the titanium implant in situ and queen lily glycoside A (RA) loaded on the lanthanum oxide (La2O3) nano-particle layer and can continuously release La < 3 + > and RA. The preparation method comprises the following steps: performing alkali heat treatment on the titanium substrate; a La (OH) 3 coating is synthesized on the surface in situ through a hydrothermal reaction; the La2O3 nano-particles are calcined and converted into a La2O3 nano-particle layer with a porous structure; and finally loading RA through an impregnation method. The coating can effectively remove ROS, regulate immune inflammatory response, promote osteogenic differentiation and inhibit osteoclast activity, thereby remarkably promoting osseointegration. The problem of osseointegration under the osteoporosis pathological microenvironment is effectively solved, the preparation process is simple and controllable, and the composition is suitable for bone defect repair of osteoporosis patients and has important clinical application value.

The invention discloses a therapeutic nano-vesicle preparation rich in mitochondrial functional protein, a preparation method of the therapeutic nano-vesicle preparation and application of the therapeutic nano-vesicle preparation in treatment of radioactive skin injury. The preparation method comprises the following steps: culturing, amplifying and cleaning umbilical cord mesenchymal stem cells, dispersing the umbilical cord mesenchymal stem cells in a suspension, mechanically extruding the umbilical cord mesenchymal stem cells into a crude solution through a multistage aperture polycarbonate membrane, and centrifuging, concentrating and purifying the crude solution to obtain the preparation. The preparation has the remarkable advantages that local administration can be realized, inflammation can be quickly inhibited, oxidative stress is reduced, and a repair pathway is activated, so that the preparation is suitable for treating acute radioactive skin injury; the preparation method is easy to standardize and scale, high in stability and convenient for emergency storage and delivery, and avoids the defects of cell therapy; a plurality of targets such as immune inflammation, oxidative stress and the like can be synergistically regulated, the biological effect of hUMSCs is simulated and partially replaced, and the limitation caused by the cell survival rate and the microenvironment dependency is avoided; the key function of hUMSCs is covered in function, and the clinical feasibility, safety and emergency suitability of the application level are higher.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a functional hydrogel microsphere and a preparation method and application thereof, and relates to the technical field of medicines.The preparation method comprises the steps that a hyaluronic acid methacrylic acid precursor solution and an IL-1beta shRNA adenovirus stock solution are mixed to obtain an Ad-atHAMA precursor solution; preparing the Ad (at) HAMA precursor solution through an oil-in-water micro-fluidic technology to obtain an Ad (at) HAMA microsphere; and sequentially adding the Ad (at) HAMA microspheres, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide into a 2-morpholinoethanesulfonic acid buffer solution, carrying out activating treatment, adding E selectin, and incubating to obtain the functionalized hydrogel microspheres. The functionalized hydrogel microspheres can inhibit a related mechanism of acute spinal cord injury pathological progress and promote neural function repair by targeting adsorption of neutrophil to regulate Nets-triggered innate immune inflammation cascade.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The invention provides a skin repairing composition for relieving red, itching and dry symptoms of sensitive skin and application, and belongs to the technical field of cosmetics. The composition comprises an effective amount of an extract of at least two algae selected from the group consisting of Phaeodactylum tricornutum, Spirulina, Chlorella and Micrococcus, and optionally comprises other skin repair ingredients cooperating therewith. The skin repair composition for relieving red, itching and dry symptoms of sensitive skin simultaneously and synergistically intervenes four major causes of sensitive skin formation, namely barrier damage, hyperneurosis, immune inflammation and micro-ecological imbalance, breaks vicious circle and establishes a repair closed loop by utilizing the multiple effects of specific algae active ingredients, and has the effects of relieving the symptoms of red, itching and dry symptoms of sensitive skin and relieving the symptoms of red, itching and dry symptoms of sensitive skin. Therefore, the problems of red skin, itching skin, dry skin and the like are radically relieved.

The invention discloses a fracture risk prediction method and system, and relates to the technical field of health management. According to the prediction method, serious sarcopenia is selected to diagnose and assess the sarcopenia state, the ratio of monocytes to lymphocytes reflects the immune inflammation level, the prediction model is constructed in combination with the femoral neck bone mineral density T value, and the fracture risk influence factors are comprehensively covered; and the risk identification capability on special high-risk groups with sarcopenia, immune dysfunction and the like is effectively improved. And secondly, only three target independent variables are selected, and the three target independent variables are indexes which can be directly obtained or simply calculated in clinical routine examination, so that the data collection difficulty is greatly reduced. Meanwhile, the prediction model is visualized through a column diagram, complex calculation is not needed, a clinician can quickly inquire the fracture risk score through the actual value of the target subject, and the method is suitable for being efficiently applied to conventional outpatient service, hospitalization and other scenes.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

This invention discloses a method, system, and medium for dynamic prediction of pregnancy complications in SLE patients, belonging to the field of medical information technology. It aims to solve the technical problems of existing risk assessment methods, such as the inability to effectively integrate multi-dimensional time-series data and the lack of causal mechanism analysis of the dynamic evolution of risk, resulting in biased, delayed, and clinically inoperable prediction results. The method includes the following steps: S1: Acquiring multimodal health data of the target patient during pregnancy as a time series; S2: Based on the multimodal health data, constructing and updating a dynamic patient profile reflecting the patient's psychosocial state, immune inflammatory activity, and target organ function; S3: Inputting the dynamic patient profile into a trained risk prediction model. This invention, by constructing a dynamic patient profile and employing a time-series deep learning model for risk prediction, achieves a comprehensive, dynamic, and mechanistically transparent risk assessment of pregnancy complications in SLE patients.

The invention discloses a layered microneedle patch as well as a preparation method and application thereof, and belongs to the field of biological medicines. Wherein the needle body tip is composed of a therapeutic agent and L-arginine shell modified glycan gel, has excellent biocompatibility and free DNA removal ability, and can deliver deferoxamine and synergistically regulate and control inflammation signals; the upper part of the needle body and the substrate are made of low-molecular-weight hyaluronic acid which is quickly dissolved after being in contact with skin, so that the needle tip is quickly separated from the substrate, the needle tip is retained at a diseased region, and effective deposition of a medicine at the diseased region is ensured; the layered microneedle can slowly release deferoxamine through pH response so as to inhibit ferroptosis; the modified chitosan can efficiently remove free DNA so as to reduce immune inflammation and cooperatively block immune inflammation circulation. The preparation process of the layered microneedle is controllable, the material biocompatibility is excellent, and the layered microneedle has the advantages of efficient targeted delivery, long-acting release and synergistic treatment, so that a feasible strategy is provided for psoriasis treatment.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

The invention discloses a construction method of a sensitive skin animal model, and belongs to the technical field of animal model construction. According to the method disclosed by the invention, the sensitive skin animal model is constructed by smearing the lauryl sodium sulfate on the back skin of the mouse after hair removal in combination with veratrine or capsaicin, so that physiological indexes of human sensitive skin can be simulated; key pathological processes of human sensitive skin can be simulated by detecting key pathological indexes such as skin barrier damage, nerve and blood vessel high reactivity, immune inflammation and the like, natural pathophysiological processes of human sensitive skin can be simulated, and pathogenesis of sensitive skin is basically covered; barrier destruction of mouse skin, high reactivity of nerve and blood vessels and inflammatory response are induced, and clinical practice is met. In addition, the method is good in repeatability, high in safety and easy and convenient to operate, sensitive skin medicine screening and personalized treatment scheme development can be promoted, the research and development period of sensitive skin related treatment schemes is shortened, and the application prospect is good.

The invention discloses an application of KL-6 alone or in combination with other immune inflammation markers in complex silicosis recognition and lung function injury evaluation. The invention firstly discloses application of KL-6 in preparation of a product for complex silicosis identification and lung function injury evaluation. The invention further discloses application of the KL-6 combined with other immune inflammation markers in preparation of products for complex silicosis recognition and lung function injury evaluation. According to the invention, KL-6 is taken as a core, LDH and ESR are combined to construct a diagnosis scheme, and complex silicosis and dust exposed persons or simple silicosis can be distinguished; meanwhile, KL-6 is in significant negative correlation with lung function parameters and can assist in evaluating the severity of diseases and the condition of lung function impairment. The method is rapid and accurate in diagnosis, easy and convenient to operate, controllable in cost, capable of achieving batch detection, suitable for health monitoring of high-risk occupational people and capable of providing efficient technical support for early recognition of complex silicosis, lung function injury evaluation and clinical decision making.

The invention discloses a model for early prediction of acute kidney injury risk after geriatric sepsis patients are transferred into ICU based on clinical variables and immune inflammation indexes, 627 geriatric sepsis patients are included in the research, and the clinical variables and immune inflammation indexes of the geriatric sepsis patients in the ICU within 24 hours are collected; clinical variables of the first 6 ranked and immune inflammation indexes of the first 4 ranked related to acute kidney injury are screened out, prediction models are constructed through four machine learning algorithms respectively, the model prediction performance of the XGBoost algorithm is the best, the model prediction performance of the logistic regression algorithm is the second, and the model prediction performance of the XGBoost algorithm is the best. And a visual column diagram is made according to a logistic regression algorithm, and an early prediction model with good accuracy is established.

The present disclosure provides antibodies that bind to CD40, and methods of using them to modulate immunity in a patient in need thereof and to treat autoimmune disorders or immunoinflammatory disorders.

The application discloses a kind of S3B polypeptide with SHP2 as action target point and its application in treating tumor and inflammation.The amino acid sequence of the polypeptide is RLLREEEYVAPPRGPLPTLQVVPL, the amino acid sequence of transmembrane peptide included in the polypeptide is TAT:YGRKKRRQRRR, the polypeptide can enter cell after being wrapped by liposome, inhibits QPCTL enzyme activity, promotes the degradation of SHP2 protein, thereby playing the role of inhibiting tumor cell proliferation, migration and growth, etc., to achieve the purpose of treating tumor and other diseases.The application provides a certain reference for treating SHP2 related tumor or immune inflammatory disease and developing new SHP2 degradation drug.

This invention discloses the application of C5aR1 antagonists and / or IL-1β inhibitors in the preparation of drugs for treating congenital heart disease with pulmonary hypovascularity. This invention breaks through the limitations of traditional single surgical procedures, providing for the first time a targeted, effective, and safe drug treatment strategy from a novel perspective of immune inflammation regulation. This strategy not only effectively promotes lung development and improves patients' physiological indicators, but also safeguards high-risk surgeries, ultimately comprehensively improving the prognosis and quality of life for patients with congenital heart disease with pulmonary hypovascularity.

The invention relates to a bilobalide A modified polycaprolactone nanofiber membrane as well as a preparation method and application thereof, and relates to the technical field of composite biological materials. The nanofiber membrane is prepared from the following components: polycaprolactone and bilobalide A. The invention further discloses a preparation method of the nanofiber membrane. The bilobalide A is modified on the polycaprolactone nanofiber membrane through an electrostatic spinning technology, and the obtained functional bilobalide A modified polycaprolactone nanofiber membrane increases the hydrophilicity of polycaprolactone, promotes cell adhesion and inhibits generation of macrophages and inflammatory factors; after being implanted in a body wrapping the tissue-engineered cartilage, the material can inhibit immune inflammatory response of the tissue-engineered cartilage, maintain the form of the engineered cartilage and promote cartilage regeneration.

The present application relates to an anti-inflammatory peptide comprising one or more selected from the group consisting of amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 63 and modified amino acid sequences thereof, an anti-inflammatory composition comprising the same, and a pharmaceutical composition for preventing or treating an inflammatory disease. The anti-inflammatory peptide according to an embodiment of the present application has no cytotoxicity and has an effect of inhibiting the expression or activity of MAVS activation, immune / inflammatory activation reaction mechanisms, inflammatory cytokines, and inflammasomes, and the like, and the above peptide can be applied to an anti-inflammatory composition or a composition for treating an inflammatory disease.

The invention discloses jute homogeneous polysaccharide with an immune activation effect as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention aims to solve the technical problems of improving immune organ atrophy, caused by cyclophosphamide, of an immunosuppression model mouse, recovering morphological characteristics and blood cell quantity of the spleen and promoting generation of immune and inflammatory cytokines, so that the immune function of the mouse is recovered, and the effect of immune activation is achieved. The technical scheme is characterized in that the jute homogeneous polysaccharide is formed by connecting 3-4 parts by mole of rhamnose, 0.5-2 parts by mole of arabinose, 1-3 parts by mole of galactose and 1-2 parts by mole of galacturonic acid through glucosidic bonds.

The present invention provides use of 2-hydroxy-4-(2-hydroxy-3,5-dichlorobenzyl)aminobenzoic acid 2-camphol ester in the preparation of a drug for treating psychiatric diseases. The novel drug for treating psychiatric diseases provided by the present invention may play a role in regulating the imbalance in the excitation / inhibition of a neural circuit by means of mechanisms such as targeted nNOS-PSD95 uncoupling and the agonistic effect of the α2 GABA A receptor, and has a significant inhibitory effect on immune inflammation, which plays an important role in the development and progression of psychiatric diseases. The novel drug provided by the present invention further inhibits central inflammation on the basis of regulating the imbalance in the excitation / inhibition of a central neural circuit.

This invention discloses a traditional Chinese medicine shampoo for androgenetic alopecia caused by liver and kidney deficiency, its preparation method, and its application. Belonging to the field of traditional Chinese medicine technology, the shampoo uses processed Polygonum multiflorum, wine-processed Ligustrum lucidum, Eclipta prostrata, ginseng, Angelica sinensis, safflower, Salvia miltiorrhiza, Platycladus orientalis leaves, mulberry leaves, honey-processed mulberry bark, Sophora flavescens, Cnidium monnieri, Paeonia suffruticosa, Cercis chinensis bark, ginger, Sapindus mukorossi, Gleditsia sinensis, and Clematis chinensis as raw materials, prepared through water extraction and concentration. This invention achieves both symptomatic and root-cause treatment, addressing both the underlying cause and symptoms. It intervenes in androgenetic alopecia through the HIF-1 / VEGE and IL-17 pathways, promoting angiogenesis and improving microcirculation in the scalp, inhibiting follicular immune inflammation, and creating a favorable environment for hair follicle growth. Compared with existing technologies, this invention has irreplaceable advantages in improving local symptoms such as oily scalp, itching, and dandruff.

The invention belongs to the technical field of medicines, and particularly relates to a low-toxicity cortex dictamni extract, a preparation method, a pharmaceutical composition and application. Specifically, according to the low-toxicity cortex dictamni extract, the dictamnine content is lower than 50 ppm, and the fraxinellone content is lower than 250 ppm. The hepatotoxicity of the extract is greatly reduced, and the extract has a good effect of inhibiting release of histamine and beta-Hex, so that the extract can be used for preparing medicines for treating allergic or immune inflammation related diseases. The invention provides the densefruit pittany root-bark extract which is safer and more effective and the preparation method thereof, so that the densefruit pittany root-bark extract has a good application prospect.

The application relates to a rapamycin-G4H nanocapsule, a preparation method and application thereof. The preparation method of the rapamycin-G4H nanocapsule comprises the following steps: S1. preparing a rapamycin micelle by adopting a film hydration method; S2. modifying a dibenzocyclooctyne amplification primer on the surface of the rapamycin micelle through a click chemistry reaction to obtain a rapamycin micelle modified with the amplification primer; S3. taking a linear DNA molecule as a template, and synthesizing a circular amplification template through an intramolecular cyclization reaction; and S4. incubating the circular amplification template, the rapamycin micelle modified with the amplification primer, a thermophilic DNA polymerase, a pyrophosphatase, dNTP and Co-G4-haem DNAzyme under the condition of a thermophilic DNA polymerase reaction buffer. The rapamycin-G4H nanocapsule can play an efficient antioxidant stress and immune inflammatory regulation function, can improve the intraocular microenvironment of a glaucoma patient, and can inhibit the continuous apoptosis of retinal ganglion cells.

This invention provides a method for establishing a rat model of COPD to study the medicinal uses and pharmacological effects of Liuwei Buqi Decoction in the treatment of COPD. The traditional Chinese medicines in Liuwei Buqi Decoction are ginseng, astragalus, alpinia oxyphylla, polygonatum odoratum, tangerine peel, and cinnamon. This application provides a basis for the syndrome differentiation and treatment strategy of Liuwei Buqi Decoction by exploring the molecular mechanisms by which Liuwei Buqi Decoction regulates the COPD inflammatory immune network and the molecular mechanisms by which it regulates the lung-gut microecological axis and the inflammatory immune network. Taking the high-incidence syndromes of major diseases during the TCM-advantage stage as a starting point, and based on clinical needs, this study, building upon previous clinical research, uses various techniques such as scRNA-seq, CBA, and metagenomics to explore the molecular mechanism by which Liuwei Buqi Decoction improves airway immune inflammation by regulating the lung microecology in rats with COPD lung-kidney qi deficiency syndrome from the perspective of regulating the lung immune microenvironment and alveolar macrophage polarization. Its mechanism of action was further studied and verified through in vitro experiments.

The invention discloses a Karenia mikimotoi red tide biotoxicity and risk assessment method, and belongs to the field of marine environment monitoring and ecological risk assessment. The method comprises the steps of karenia mikimotoi culture, marine model fish model establishment, karenia mikimotoi exposure, multi-system toxicity index detection and data analysis. By integrating five toxic pathways (hemolysis injury, detoxification metabolism, oxidative stress, immune inflammation and reproductive function), systematic evaluation from a micromechanism (gene / cell) to a macroscopic effect (tissue / individual) is realized, and a toxic action mechanism is comprehensively revealed. By means of LDH, blood sugar, ROS and other sub-lethal indexes, early warning is achieved before irreversible injury occurs, and more abundant response time is provided for red tide disaster prevention. Traditional phenomenon observation is broken through, multi-system dysfunction caused by energy depletion, immune attack and other new mechanisms of Karenia mikimotoi is revealed through a key gene expression mode, and a new target is provided for toxicity prevention and control.